TITLE

Adverse events monitoring as a routine component of vaccine clinical trials: Evidence from the

AUTHOR(S)
Mayans, Marti Vall; Robertson, Susan E.
PUB. DATE
September 2000
SOURCE
Bulletin of the World Health Organization;2000, Vol. 78 Issue 9, p1166
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the use of the World Health Organization (WHO) Vaccine Trial Registry to assess whether and how investigators are monitoring adverse events following immunization (AEFI) in vaccine trials. Objective of the WHO Immunization Safety Priority; AEFI according to reports; Points for monitoring AEFIs in vaccine clinical trials.
ACCESSION #
3556666

 

Related Articles

  • Adverse events monitoring as a routine component of vaccine clinical trials: Evidence from the... Mayans, Marti Vall; Robertson, Susan E. // Bulletin of the World Health Organization;2000, Vol. 78 Issue 9, p1166 

    Reports on the use of the World Health Organization (WHO) Vaccine Trial Registry to assess whether and how investigators are monitoring adverse events following immunization (AEFI) in vaccine trials. Objective of the WHO Immunization Safety Priority; AEFI according to reports; Points for...

  • Basic toxicity assessment.  // WHO Technical Report Series;2004, Issue 927, p45 

    The article discusses the World Health Organization guidelines in evaluating the potential toxic effects of a vaccine. The guidelines specified the parameters relevant in designing animal toxicology studies. It clarified that the potential effects of the product should be evaluated with regard...

  • Toxicity assessment.  // WHO Technical Report Series;2004, Issue 927, p44 

    The article explains the importance of toxicity assessment in the evolving field of vaccine development. The scientific judgment in nonclinical safety studies should be employed in data interpretation from the studies concerning the risk-benefit ratio, animal testing and dosing. Before vaccines...

  • Vaccine formulation and delivery device.  // WHO Technical Report Series;2004, Issue 927, p52 

    The article presents the section of the World Health Organization guidelines on nonclinical evaluation of vaccines concerning vaccine formulation and the delivery device. The delivery device and vaccine development whether in liquid form, capsules or powder, can have an affect on the process of...

  • Ultimate test for HIV vaccines. Brown, Phyllida // New Scientist;10/26/91, Vol. 132 Issue 1792, p17 

    Reports that the World Health Organization has chosen Uganda, Rwanda, Brazil and Thailand for the first field trials of HIV vaccines in 1991. Request given by the four countries for the trial in response to their AIDS epidemics; Insufficiency of education, information and communication to...

  • Progress Toward Laboratory Containment of Poliovirus After Polio Eradication. Wolff, Christopher; Roesel, Sigrun; Lipskaya, Galina; Landaverde, Mauricio; Humayun, Asghar; Withana, Nalini; Ramamurty, Nalini; Tomori, Oyewale; Okiror, Samuel Oumo; Salla, Mbaye; Dowdle, Walter // Journal of Infectious Diseases;Nov2014 Supplement, Vol. 210 Issue suppl_1, pS454 

    Background. The first steps (phase 1) toward laboratory containment of poliovirus after eradication are a national survey of biomedical facilities and a global inventory of such facilities retaining wild poliovirus (WPV) infectious and potentially infectious materials.Methods. We reviewed...

  • Serologic Response to Inactivated Poliovirus Vaccine: A Randomized Clinical Trial Comparing 2 Vaccination Schedules in Puerto Rico. Dayan, Gustavo H.; Thorley, Margaret; Yamamura, Yasuhiro; Rodríguez, Nayra; McLaughlin, Steve; Torres, Lourdes M.; Seda, Antonio; Carbia, Marcia; Alexander, Lorraine N.; Caceres, Victor; Pallansch, Mark A. // Journal of Infectious Diseases;1/1/2007, Vol. 195 Issue 1, p12 

    Background. The World Health Organization (WHO) recommends the discontinuation of oral poliovirus vaccine after eradication of wild poliovirus. Studies assessing inactivated poliovirus vaccine (IPV) immunogenicity tropical countries, using the WHO Expanded Programme on Immunization (EPI)...

  • Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations. Hanekom, Willem A.; Dockrell, Hazel M.; Ottenhoff, Tom H. M.; Doherty, T. Mark; Fletcher, Helen; McShane, Helen; Weichold, Frank F.; Hoft, Dan F.; Parida, Shreemanta K.; Fruth, Uli J. // PLoS Medicine;Jul2007, Vol. 5 Issue 7, pe145 

    Willem Hanekom and colleagues make recommendations on assay harmonization for novel tuberculosis vaccine trials.

  • The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial. Piaggio, Gilda; Elbourne, Diana; Schulz, Kenneth F.; Villar, José; Pinol, Alain P. Y.; Gülmezoglu, A. Metin // BMC Medical Research Methodology;2003, Vol. 3, p19 

    Background: The aim of this article is to explore ways in which selection bias and ascertainment bias can be reduced and investigated in trials, by using the example of a drug trial carried out in both developed and developing countries in hospital delivery wards. Methods: We describe an...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics